Should Opioids Be Used Solely For Severe Pain? FDA Seeks Expert Advice
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is holding a public meeting in February to obtain information on opioid treatment for chronic pain; FDA seeks data to assess whether to restrict use and establish a maximum daily dose.
You may also be interested in...
Citizen Petition Seeks Limited Opioid Drug Indication To Curb Overuse And Abuse
Physician group appeals for FDA to rescind approval for moderate non-cancer pain and Massachusetts Democrat Rep. William Keating introduces legislation that would bar FDA approval of a non-tamper-resistant opioid drug if the same active moiety already was approved in a tamper-resistant product.
Opioid REMS Requires Sponsors To Launch Prescriber Training CME Within 9 Months
By the third year of continuing medical education efforts, FDA expects 60% of those who wrote a prescription for a long-acting/extended-release opioid in 2011 to receive training.
Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies, the agency’s policy for using background music in direct-to-consumer advertising, and the FDA’s new incoming principal deputy commissioner.